293 related articles for article (PubMed ID: 25046202)
1. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
2. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
3. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
4. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
5. Personalized medicine benefits patients in early trials: matching targeted therapies with gene mutations is associated with better outcomes, even in phase 1 studies.
Printz C
Cancer; 2012 Oct; 118(20):4911-2. PubMed ID: 23042614
[No Abstract] [Full Text] [Related]
6. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
Hollebecque A; Massard C; Soria JC
Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine in oncology: tailoring the right drug to the right patient.
Jiang Y; Wang M
Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441
[TBL] [Abstract][Full Text] [Related]
8. Personalized Approaches to Gastrointestinal Cancers: Importance of Integrating Genomic Information to Guide Therapy.
He J; Ahuja N
Surg Clin North Am; 2015 Oct; 95(5):1081-94. PubMed ID: 26315525
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.
Cronin M; Ross JS
Biomark Med; 2011 Jun; 5(3):293-305. PubMed ID: 21657839
[TBL] [Abstract][Full Text] [Related]
10. Impact of tumor sequencing on the use of anticancer drugs.
Thomas F; Desmedt C; Aftimos P; Awada A
Curr Opin Oncol; 2014 May; 26(3):347-56. PubMed ID: 24709974
[TBL] [Abstract][Full Text] [Related]
11. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.
Wang E; Zaman N; Mcgee S; Milanese JS; Masoudi-Nejad A; O'Connor-McCourt M
Semin Cancer Biol; 2015 Feb; 30():4-12. PubMed ID: 24747696
[TBL] [Abstract][Full Text] [Related]
12. From genomic landscapes to personalized cancer management-is there a roadmap?
Swanton C; Caldas C
Ann N Y Acad Sci; 2010 Oct; 1210():34-44. PubMed ID: 20973797
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-driven patient selection for early clinical trials.
Dienstmann R; Rodon J; Tabernero J
Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
[TBL] [Abstract][Full Text] [Related]
14. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
15. Biology-driven phase II trials: what is the optimal model for molecular selection?
Andre F; Delaloge S; Soria JC
J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
[No Abstract] [Full Text] [Related]
16. Personalized medicine: present and future of breast cancer management.
Sabatier R; Gonçalves A; Bertucci F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
[TBL] [Abstract][Full Text] [Related]
17. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?
Arnedos M; Soria JC; Andre F; Tursz T
Cancer Treat Rev; 2014 Dec; 40(10):1192-8. PubMed ID: 25441102
[TBL] [Abstract][Full Text] [Related]
18. From cancer genomics to precision oncology--tissue's still an issue.
Cohen RL; Settleman J
Cell; 2014 Jun; 157(7):1509-14. PubMed ID: 24949964
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.
Tanabe Y; Ichikawa H; Kohno T; Yoshida H; Kubo T; Kato M; Iwasa S; Ochiai A; Yamamoto N; Fujiwara Y; Tamura K
Mol Cancer; 2016 Nov; 15(1):73. PubMed ID: 27852271
[TBL] [Abstract][Full Text] [Related]
20. [Genome sequencing and personalized medicine: perspectives and limitations].
Le Gall JY; Debré P;
Bull Acad Natl Med; 2014 Jan; 198(1):101-17. PubMed ID: 26259290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
